232 related articles for article (PubMed ID: 12632750)
1. [Stratification of cardiac risk in unstable angina: value of troponin measurements].
Chérif A; Messaoudi H; Mourali S; Ezzar T; Boussaada R; Mechmèche R
Tunis Med; 2002 Oct; 80(10):581-3. PubMed ID: 12632750
[TBL] [Abstract][Full Text] [Related]
2. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
3. Redefining medical treatment in the management of unstable angina.
Braunwald E; Califf RM; Cannon CP; Fox KA; Fuster V; Gibler WB; Harrington RA; King SB; Kleiman NS; Theroux P; Topol EJ; Van de Werf F; White HD; Willerson JT
Am J Med; 2000 Jan; 108(1):41-53. PubMed ID: 11059440
[TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
[No Abstract] [Full Text] [Related]
5. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
6. [Risk stratification in acute coronary syndrome].
Goldmann BU; Hamm CW
Herz; 2001 Apr; 26 Suppl 1():24-9. PubMed ID: 11349623
[TBL] [Abstract][Full Text] [Related]
7. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
Lenderink T; Boersma E; Heeschen C; Vahanian A; de Boer MJ; Umans V; van den Brand MJ; Hamm CW; Simoons ML;
Eur Heart J; 2003 Jan; 24(1):77-85. PubMed ID: 12559939
[TBL] [Abstract][Full Text] [Related]
8. [Glycoprotein IIb/IIIa antagonists].
Hennemann A
Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
[No Abstract] [Full Text] [Related]
9. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
10. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
11. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
12. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
[TBL] [Abstract][Full Text] [Related]
13. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
14. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
16. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
17. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Ramanathan A; Kleiman NS
Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
[No Abstract] [Full Text] [Related]
18. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Steinhubl SR; Moliterno DJ
Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies in cardiology].
Legrand V
Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
